CELC vs. NHC, VRDN, AHCO, CDNA, AGL, PNTG, AVAH, CSTL, GRAL, and FLGT
Should you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include National HealthCare (NHC), Viridian Therapeutics (VRDN), AdaptHealth (AHCO), CareDx (CDNA), agilon health (AGL), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Castle Biosciences (CSTL), Grail (GRAL), and Fulgent Genetics (FLGT). These companies are all part of the "healthcare" industry.
Celcuity vs.
Celcuity (NASDAQ:CELC) and National HealthCare (NYSE:NHC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
63.3% of Celcuity shares are owned by institutional investors. Comparatively, 56.4% of National HealthCare shares are owned by institutional investors. 15.8% of Celcuity shares are owned by company insiders. Comparatively, 13.8% of National HealthCare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
National HealthCare has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than National HealthCare, indicating that it is currently the more affordable of the two stocks.
Celcuity has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, National HealthCare has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
Celcuity received 335 more outperform votes than National HealthCare when rated by MarketBeat users. However, 100.00% of users gave National HealthCare an outperform vote while only 67.54% of users gave Celcuity an outperform vote.
Celcuity currently has a consensus target price of $29.17, indicating a potential upside of 160.58%. Given Celcuity's stronger consensus rating and higher possible upside, equities analysts plainly believe Celcuity is more favorable than National HealthCare.
National HealthCare has a net margin of 10.03% compared to Celcuity's net margin of 0.00%. National HealthCare's return on equity of 6.87% beat Celcuity's return on equity.
In the previous week, Celcuity had 2 more articles in the media than National HealthCare. MarketBeat recorded 3 mentions for Celcuity and 1 mentions for National HealthCare. Celcuity's average media sentiment score of 1.01 beat National HealthCare's score of 0.00 indicating that Celcuity is being referred to more favorably in the media.
Summary
Celcuity beats National HealthCare on 10 of the 18 factors compared between the two stocks.
Get Celcuity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Celcuity Competitors List
Related Companies and Tools
This page (NASDAQ:CELC) was last updated on 1/21/2025 by MarketBeat.com Staff